NCT05135052: EPIC-Skin

Rhenium-Skin Cancer Therapy (SCT) for the Treatment of Non-Melanoma Skin Cancer.

Active, enrolled NA Last updated 14 May 2025

What this trial tests

NA trial testing Rhenium-SCT in Non-melanoma Skin Cancer in 210 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 January 2022

Primary endpoint
15 July 2026

15 May 2027

Quick facts

Lead sponsor	OncoBeta Therapeutics
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	210
Start date	17 January 2022
Primary completion	15 July 2026
Estimated completion	15 May 2027
Sites	7 locations across South Africa, Austria, United Kingdom, Germany, Australia

Drugs / interventions tested

• Rhenium-SCT

Conditions studied

• Non-melanoma Skin Cancer — all drugs for Non-melanoma Skin Cancer →

Sponsor

OncoBeta Therapeutics

Who can join

18 and older, any sex, with Non-melanoma Skin Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy of Personalised Irradiation with Rhenium-Skin Cancer Therapy (SCT) for the treatment of non-melanoma skin cancer; a phase IV multi-centre, international, open label, single arm study.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

1. Rhenium Radioisotopes for Medicine, a Focus on Production and Applications.
   Uccelli L, Martini P, Urso L, Ghirardi T, et al · · 2022 · cited 16× · PMID 36014521 · DOI 10.3390/molecules27165283
2. Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.
   Sharma S, Pandey MK. · · 2023 · cited 13× · PMID 37895931 · DOI 10.3390/ph16101460
3. Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study.
   Baxi S, Vohra S, Hong A, Mulholland N, et al · · 2024 · cited 5× · PMID 39025650 · DOI 10.2967/jnumed.124.267988
4. Efficacy, Safety, and Patient Reported Outcomes of Rhenium-Skin Cancer Therapy for Non-Melanoma Skin Cancer: 1-Year Results from the EPIC-Skin Study.
   Cardaci G, Baxi S, Vohra S, Allison C, et al · · 2025 · cited 2× · PMID 40575594 · DOI 10.1016/j.adro.2025.101802
5. Patient-Orientated Evaluation of Treatment of Non-Melanoma Skin Cancer with Rhenium-188 Compared to Surgery.
   Krönert MIC, Schwarzenböck SM, Kurth J, Heuschkel M, et al · · 2024 · cited 2× · PMID 38727478 · DOI 10.3390/healthcare12090921
6. Targeted <i>β</i>-therapy with rhenium-aided therapy for cutaneous lesions: a systematic review and meta-analysis.
   Sadeghpour S, Sadeghi R, Aghaee A, Saber Tanha A, et al · · 2025 · PMID 41393150 · DOI 10.3389/fmed.2025.1707729